$1.54
▲ +$0.05
(+3.36%)
Vol 1.2M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$87.7M
ROE
-310.2%
D/E
0.00
Beta
-0.16
52W
$1–$5
Wall Street Consensus
13 analysts · Apr 20265
Strong Buy
6
Buy
1
Hold
1
Sell
0
Strong Sell
84.6%
Buy Rating
Price Chart
Similar Stocks
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
PEPG
PepGen Inc
$447.6M
GNLX
Genelux Corp
$165.9M
SGMO
Sangamo Therapeutics Inc
$141.3M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CRDF
Cardiff Oncology Inc
$189.3M
CADL
Candel Therapeutics Inc
$310.2M
ALDX
Aldeyra Therapeutics Inc
$99.9M
SPRB
Spruce Biosciences, Inc
$93.2M
About Biomea Fusion, Inc. - Common Stock
На жаль, немає загальновідомої компанії під назвою BMEA в галузі біотехнологій. Можливо, назва вказана невірно, або це внутрішня назва компанії. Щоб надати точний опис, потрібна більш конкретна інформація про компанію.
Earnings
Beat rate: 60.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.26 | $0.27 | +$0.53 |
| Sep 2025 | $-0.26 | $-0.27 | $-0.01 |
| Jun 2025 | $-0.54 | $-0.51 | +$0.03 |
| Mar 2025 | $-0.62 | $-0.80 | $-0.18 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$32.8M | -$29.3M | -$29.3M | -$20.7M | -$16.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -243.9% | -243.9% | -243.9% | -243.9% | -310.2% | -310.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.68 | 3.68 | 3.68 | 3.68 | 3.18 | 3.18 |
Key Ratios
ROA (TTM)
-145.4%
P/B
2.7
EPS (TTM)
$-2.39
CF/Share
$-3.27
52W High
$4.59
52W Low
$0.87
$0.87
52-Week Range
$4.59
Financial Health
Free Cash Flow
-$11.6M
Net Debt
-$39.8M
Cash
$46.6M
Total Debt
$6.9M
As of Sep 30, 2025
How does BMEA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
BMEA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.7
▲
11%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
BMEA profitability vs Biotechnology peers
ROE
-310.2%
▼
361%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-145.4%
▼
211%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
BMEA financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
3.2
▼
28%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
-0.2
▼
117%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
BMEA fundamentals radar
BMEA
Peer median
Industry
BMEA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BMEA vs peers: key metrics
Top Holders
Top 5: 23.05%FMR, LLC
12.47%
$11.6M
Vanguard Group Inc
4.20%
$3.9M
Aisling Capital Management …
2.90%
$2.7M
Woodline Partners LP
1.84%
$1.7M
Marshall Wace LLP
1.64%
$1.5M
As of Dec 31, 2025
Latest News
No related news yet